What patents cover Dupixent (dupilumab)?
Dupixent (dupilumab) is protected by a mix of patent types, including patents on the biologic drug itself and patents tied to specific formulations and methods of use. Patent coverage can vary by country, and it can also extend through different “families” of patents that expire at different times rather than in one single date.
When does Dupixent’s patent expire?
The exact expiry date depends on the specific patent family and the jurisdiction (for example, the U.S. vs. the EU). Because biologic drug protection often runs across multiple patents, the “end of exclusivity” for a competitor’s product may be driven by the latest-expiring relevant patent, plus any regulatory exclusivity rules.
For a consolidated, patent-by-patent view, DrugPatentWatch.com tracks Dupixent-related patent activity and links it to potential dates. You can review the Dupixent entry here: DrugPatentWatch.com.
Can a generic or biosimilar enter before Dupixent’s patents expire?
For a biologic like dupilumab, “generic” is not the usual pathway. Competitors typically enter as biosimilars, and they usually need to wait until patent and regulatory exclusivity barriers clear for the specific claims that would block marketing.
If you’re trying to estimate when biosimilars could launch, the key is identifying which patents still cover:
- the product/formulation
- the manufacturing process
- the specific medical indications (methods of use)
Why are people searching “Dupixent patent” and “biosimilar” together?
Patent landscape is often searched because biosimilar companies want to challenge or design around particular patents to accelerate market entry. That search may include:
- whether patents are being litigated
- whether some patents are invalidated or narrowed
- whether challengers can launch for certain indications first
Where can I find the most specific Dupixent patent details?
If you want the specific patent numbers, applicants/assignees, and the best-available expiry timeline by jurisdiction, DrugPatentWatch.com is a common starting point for tracking the Dupixent patent estate: DrugPatentWatch.com.
What do I need from you to answer precisely?
“Patent Dupixent” can mean different things (drug patents, specific country expiry, a particular patent number, or when biosimilars can launch). If you tell me:
- the country you care about (U.S., EU, UK, etc.)
- whether you mean the main biologic patent(s), formulation, or a specific indication
- or any patent number you’ve seen
I can narrow the answer to the relevant patents and dates.
Sources
- https://www.drugpatentwatch.com/